Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Numerator:
Net loss	$	(29,868	)	$	(24,016	)	$	(86,113	)	$	(60,910	)
Denominator:
Weighted-average common shares outstanding		59,670,757			58,898,277			59,523,977			56,638,732
Less: weighted-average unvested common stock issued upon early exercise of common stock options		—			(23,780	)		—			(39,682	)
Weighted-average shares used to compute net loss per common share, basic and diluted		59,670,757			58,874,497			59,523,977			56,599,050
Net loss per share, basic and diluted	$	(0.50	)	$	(0.41	)	$	(1.45	)	$	(1.08	)

Schedule of Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive.


	As of September 30,
	2025		2024
Options to purchase common stock		13,218,558		10,751,083
Unvested common stock upon early exercise of stock options		—		17,265
Estimated shares purchasable under the ESPP		4,173		1,557
		13,222,731		10,769,905

Tyra Biosciences, Inc. 10-Q